BioCryst to Showcase New HAE Data at EAACI 2026, Highlighting ORLADEYO and Navenibart
Event summary
- BioCryst will present seven abstracts on hereditary angioedema (HAE) at the EAACI Annual Meeting in Istanbul from June 12-15, 2026.
- Six abstracts focus on ORLADEYO (berotralstat), including real-world outcomes and clinical trial data in pediatric and adult patients.
- One abstract features clinical trial outcomes for navenibart, a long-acting monoclonal antibody plasma kallikrein inhibitor.
- ORLADEYO is the first and only oral prophylactic therapy for HAE patients aged 2 and older.
- Navenibart is being evaluated for potential best-in-class dosing every 3 or 6 months.
The big picture
BioCryst's presentation at the EAACI Annual Meeting underscores its focus on advancing treatments for hereditary angioedema. The company's dual approach with ORLADEYO and navenibart aims to address both immediate and long-term prophylaxis needs, potentially strengthening its market position. The data presented could influence investor sentiment and strategic partnerships in the rare disease space.
What we're watching
- Clinical Efficacy
- How the new data on ORLADEYO and navenibart will impact their competitive positioning in the HAE market.
- Regulatory Pathway
- Whether the positive outcomes from the clinical trials will accelerate the regulatory approval process for navenibart.
- Market Adoption
- The pace at which ORLADEYO and navenibart can gain market share in the HAE treatment landscape.
Related topics